BioNTech SE (short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies, and small molecule immunomodulators as treatment options for cancer.
The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process. In 2020, BioNTech’s RNA vaccine candidate for preventing COVID-19 infections, BNT162b2, was in Phase III clinical trials in the United States. On 2 December 2020, temporary Human Medicines Regulations (HMR) authorization was granted by the United Kingdom government for BNT162b2 vaccinations within the UK.
Click to see more
BioNTech SE Details
Operating Status:Active
Business TypePublic
HeadquartersMainz, Germany
Founded Date 2008
Organization CEO Uğur Şahin
FoundersUğur Şahin, Özlem Türeci, Christoph Huber, Andreas Strüngmann, Thomas Strüngmann, Michael Motschmann, Helmut Jeggle
The potential efficacy in the approved Pfizer-BioNTech and Moderna vaccines is spurring a delay in second dose administration by some nations, especially those with limited supplies of the jabs.
Notably, the World Health Organization has approved two different versions of the AstraZeneca vaccine that were found out to be approximately 63% effective.
